Fairfield Bush & CO. reduced its holdings in athenahealth, Inc. (NASDAQ:ATHN) by 49.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,503 shares of the health services provider’s stock after selling 2,420 shares during the quarter. Fairfield Bush & CO.’s holdings in athenahealth were worth $352,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Turner Investments LLC bought a new stake in shares of athenahealth in the second quarter valued at about $105,000. FNY Partners Fund LP lifted its stake in shares of athenahealth by 1,900.0% in the first quarter. FNY Partners Fund LP now owns 1,000 shares of the health services provider’s stock valued at $112,000 after buying an additional 950 shares during the period. Bessemer Group Inc. lifted its stake in shares of athenahealth by 13.7% in the second quarter. Bessemer Group Inc. now owns 938 shares of the health services provider’s stock valued at $132,000 after buying an additional 113 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of athenahealth by 7.7% in the second quarter. The Manufacturers Life Insurance Company now owns 1,179 shares of the health services provider’s stock valued at $166,000 after buying an additional 84 shares during the period. Finally, Seven Bridges Advisors LLC lifted its stake in shares of athenahealth by 5.4% in the second quarter. Seven Bridges Advisors LLC now owns 1,303 shares of the health services provider’s stock valued at $183,000 after buying an additional 67 shares during the period.

athenahealth, Inc. (NASDAQ ATHN) traded up 0.47% during mid-day trading on Wednesday, hitting $120.70. 81,924 shares of the stock traded hands. The firm’s 50-day moving average price is $129.99 and its 200-day moving average price is $130.17. athenahealth, Inc. has a 52 week low of $90.11 and a 52 week high of $158.66. The firm has a market cap of $4.82 billion, a P/E ratio of 150.88 and a beta of 1.76.

athenahealth (NASDAQ:ATHN) last issued its quarterly earnings results on Thursday, July 20th. The health services provider reported $0.51 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.39 by $0.12. athenahealth had a net margin of 2.80% and a return on equity of 6.91%. The company had revenue of $301.10 million during the quarter, compared to the consensus estimate of $298.68 million. During the same quarter in the prior year, the firm posted $0.34 EPS. The firm’s quarterly revenue was up 15.0% on a year-over-year basis. On average, equities analysts forecast that athenahealth, Inc. will post $1.91 earnings per share for the current fiscal year.

Several equities research analysts recently weighed in on the stock. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $170.00 target price (up previously from $150.00) on shares of athenahealth in a research note on Wednesday, August 2nd. Cowen and Company cut shares of athenahealth from an “outperform” rating to a “market perform” rating and increased their target price for the company from $127.00 to $133.00 in a research note on Monday, July 31st. Morgan Stanley reiterated an “equal weight” rating and issued a $125.00 target price (up previously from $108.00) on shares of athenahealth in a research note on Wednesday, August 2nd. Citigroup Inc. reiterated a “buy” rating and issued a $186.00 target price (up previously from $169.00) on shares of athenahealth in a research note on Monday, July 24th. Finally, ValuEngine upgraded shares of athenahealth from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Three equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $149.91.

In other news, Director Brandon H. Hull sold 800 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $140.01, for a total transaction of $112,008.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jonathan Bush sold 4,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $143.31, for a total transaction of $573,240.00. Following the sale, the chief executive officer now directly owns 319,807 shares of the company’s stock, valued at approximately $45,831,541.17. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,505 shares of company stock valued at $2,240,851. 3.20% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/athenahealth-inc-athn-shares-sold-by-fairfield-bush-co/1623831.html.

athenahealth Company Profile

athenahealth, Inc provides network-based medical record, revenue cycle, patient engagement, care coordination and population health services. The Company also offers Epocrates and other point-of-care mobile applications. The Company delivers majority of its service offerings through a single instance of cloud-based software, athenaNet.

Want to see what other hedge funds are holding ATHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for athenahealth, Inc. (NASDAQ:ATHN).

Institutional Ownership by Quarter for athenahealth (NASDAQ:ATHN)

Receive News & Ratings for athenahealth Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for athenahealth Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.